These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 19189856)

  • 1. Thermostable foot-and-mouth disease virus as a vaccine candidate for endemic countries: a perspective.
    Hegde NR; Maddur MS; Rao PP; Kaveri SV; Bayry J
    Vaccine; 2009 Apr; 27(16):2199-201. PubMed ID: 19189856
    [No Abstract]   [Full Text] [Related]  

  • 2. Foot and mouth disease virus vaccines.
    Rodriguez LL; Grubman MJ
    Vaccine; 2009 Nov; 27 Suppl 4():D90-4. PubMed ID: 19837296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Vaccination against foot and mouth disease: current state and perspectives].
    Visser N; Thiel HJ
    Dtsch Tierarztl Wochenschr; 2001 Dec; 108(12):522-5. PubMed ID: 11822168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Past and present vaccine development strategies for the control of foot-and-mouth disease.
    Balamurugan V; Kumar RM; Suryanarayana VV
    Acta Virol; 2004; 48(4):201-14. PubMed ID: 15745043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Point of view of KNMvD concerning foot and mouth disease marker vaccine].
    van Leeuwen JM
    Tijdschr Diergeneeskd; 2001 Sep; 126(17):585. PubMed ID: 11596520
    [No Abstract]   [Full Text] [Related]  

  • 6. The eradication of foot-and-mouth disease: a parallel problem.
    Brown F
    Dev Biol (Basel); 2001; 105():123-7; discussion 149-50. PubMed ID: 11763321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression of foot and mouth disease virus antigens in transgenic plants].
    Dus Santos MJ; Wigdorovitz A
    Rev Sci Tech; 2005 Apr; 24(1):175-87. PubMed ID: 16110887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Foot and mouth disease: a revised policy is required.
    Bayry J; Kaveri SV
    J Clin Microbiol; 2001 Oct; 39(10):3808. PubMed ID: 11599518
    [No Abstract]   [Full Text] [Related]  

  • 9. Growth kinetics and immune response of chimeric foot-and-mouth disease virus serotype 'O' produced through replication competent mini genome of serotype Asia 1, 63/72, in BHK cell lines.
    Joshi R; Chandrasekar S; Paul S; Chokkalingam AK; Saravanan T; Ahmad K; Dechamma HJ; Reddy GR; Gopinath SM; Das DN; Shaila MS; Bharath GN; Suryanarayana VV
    Virus Res; 2013 May; 173(2):299-305. PubMed ID: 23384973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Round table discussion about foot and mouth disease prevention and control. The goals and differences of opinion on how to get there].
    Vaarten J
    Tijdschr Diergeneeskd; 2001 Sep; 126(18):608-10. PubMed ID: 11596536
    [No Abstract]   [Full Text] [Related]  

  • 11. High potency vaccines induce protection against heterologous challenge with foot-and-mouth disease virus.
    Brehm KE; Kumar N; Thulke HH; Haas B
    Vaccine; 2008 Mar; 26(13):1681-7. PubMed ID: 18313814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigen and vaccine banks: technical requirements and the role of the european antigen bank in emergency foot and mouth disease vaccination.
    Lombard M; Füssel AE
    Rev Sci Tech; 2007 Apr; 26(1):117-34. PubMed ID: 17633297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The threat of peste des petits ruminants: progress in vaccine development for disease control.
    Diallo A; Minet C; Le Goff C; Berhe G; Albina E; Libeau G; Barrett T
    Vaccine; 2007 Jul; 25(30):5591-7. PubMed ID: 17399862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of immunologicals in the European union: current and emerging issues.
    Kriz NG;
    Biologicals; 2005 Dec; 33(4):247-52. PubMed ID: 16289997
    [No Abstract]   [Full Text] [Related]  

  • 15. European Pharmacopoeia foot-and-mouth disease vaccine potency testing in cattle: between test variability and its consequences.
    Goris N; Merkelbach-Peters P; Diev VI; Verloo D; Zakharov VM; Kraft HP; De Clercq K
    Vaccine; 2007 Apr; 25(17):3373-9. PubMed ID: 17227691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Making a vaccinate-to-live policy a reality in foot-and-mouth disease.
    Mackay D; Parida S; Paton D; Anderson J
    Dev Biol (Basel); 2004; 119():261-6. PubMed ID: 15742637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The effectiveness of vaccination to prevent foot and mouth disease in several species].
    Orsel K
    Tijdschr Diergeneeskd; 2008 Jan; 133(1):14-6. PubMed ID: 18260556
    [No Abstract]   [Full Text] [Related]  

  • 18. Evolving perception on the benefits of vaccination as a foot and mouth disease control policy: contributions of South America.
    Bergmann IE; Malirat V; Falczuk AJ
    Expert Rev Vaccines; 2005 Dec; 4(6):903-13. PubMed ID: 16372885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [An overview of the evolution of EV71 vaccine].
    Li M; Yin Y; Li J
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2010 Aug; 27(4):933-6. PubMed ID: 20842875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A review of the risks involved in the import of foot and mouth disease vaccinated animals and the products of such animals].
    Sutmoller P
    Tijdschr Diergeneeskd; 2004 Jun; 129(12):408-9. PubMed ID: 15232965
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.